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Summary
Objective: Aggrecan is degraded by Aggrecanases (ADAMTS-4 and –5) and MMPs, which cleave its core protein at different sites.
Transforming growth factor (TGF) is known to stimulate matrix formation in cartilage, and ADAMTS-4 production in synoviocytes. The aim
of this in-vitro study was to examine the effects of TGF on aggrecanase production in human cartilage.
Design: Expression of ADAMTS-4 and -5 in chondrocyte cultures from normal or osteoarthritic cartilage was studied at mRNA level by
RT-PCR. Aggrecanase activity was examined by western blot of aggrecanase-generated neoepitope NITEGE, and by measure of
proteoglycan degradation in cartilage explants.
Results: TGF strongly increased mRNA levels of ADAMTS-4, while ADAMTS-5 was expressed in a constitutive way in chondrocytes from
normal and osteoathritic cartilage. TGF also increased NITEGE levels and proteoglycan degradation. Addition of an aggrecanase inhibitor
blocked the increase of NITEGE, and partially inhibited proteoglycan degradation.
Conclusions: TGF stimulates ADAMTS-4 expression and aggrecan degradation in cartilage. This catabolic action seems to be partially
mediated by aggrecanases. It is, therefore, proposed that the role of TGF in cartilage matrix turnover is not limited to anabolic and
anti-catabolic actions, but also extends to selective degradation of matrix components such as aggrecan.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is characterized by progressive erosion
of articular cartilage, which finally leads to exposure of
subchondral bone. This process is accompanied by forma-
tion of osteophytes, bony outgrowths at the edges of
articular surfaces, and by synovial inflammation1. In animal
models of OA, the first response of articular cartilage to an
initial damage consists of increased proliferation and matrix
synthetis by chondrocytes2,3. This anabolic reaction gives
then place to an active process of matrix degradation,
largely carried out by metalloproteinases of the matrix
metalloproteinase (MMP) and aggrecanase families1,4.
Inflammatory cytokines such as tumor necrosis factor
(TNF) and interleukin-1 (IL-1) likely play an important role in
established osteoarthritis, since they stimulate degradation
and inhibit synthesis of cartilage matrix and also activate
production of inflammatory mediators such as prostaglan-
dins, leukotrienes, and nitric oxide1,4–6. IL-1 and TNF
concentrations increase in the osteoarthritic joint and
inhibition of IL-1 activity ameliorates cartilage damage in
animal models of disease7,8. While late OA can be ascribed
to inflammatory cytokines, the initial anabolic phase that
precedes cartilage degradation can be mimicked by
TGF5,9. This growth factor stimulates proteoglycan and
collagen synthesis10 and antagonizes the effects of IL-1 on
MMP production and proteoglycan turn-over11–13, possibly
by decrease of IL-1 receptors14. TGF also affects bone
metabolism, since it stimulates proliferation and synthetic
activity of osteoblasts and modulates osteoclastic bone
resorption15. Intra-articular injections of TGF in mouse
knees increased proteoglycan synthesis in patellar carti-
lage, and induced formation of osteophytes in a pattern
similar to that observed in a mouse model of osteoarthri-
tis9,16. A series of observations suggest however that the
effects of TGF on the joint could be more complex than
stimulation of cartilage and bone formation. Injection of the
growth factor in knees of rabbits caused a strong decrease
of proteoglycan content in cartilage17. Van Beuningen et al.
showed that injections of TGF in mouse knees stimulated
basal proteoglycan degradation, despite concomitant
inhibition of IL-1-induced degradation18. In a subsequent
paper by the same group, the growth factor increased
proteoglycan content in the superficial layer of articular
cartilage but caused severe losses of the same component
in the deep zone close to the calcified layer9. More recently,
Mi et al.19 demonstrated that overexpression of TGF in
rabbit knees, following injection of a coding adenoviral
vector, had little or no stimulatory effect on proteoglycan
synthesis, but strongly increased proteoglycan degra-
dation. In an animal model of osteoarthritis, TGF levels in
synovial fluid, 3 weeks after induction of pathology, strongly
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correlated with the level of soluble proteoglycans in the
same compartment, and pathological score of articular
cartilage at later stages of disease20. Degradation of
aggrecan, the most abundant cartilage proteoglycan, is
mainly carried out by MMPs and aggrecanases21.
Chondrocytes express different MMPs, including colla-
genases (MMP-1, -8, -13), gelatinases (MMP-2, -9),
stromelysin (MMP-3) and membrane-type MMPs4. Two
aggrecanases were recently identified as members of the
ADAMTS family (a disintegrin and metalloproteinase with
thrombospondin domain)22,23. Aggrecanase-1 and -2
(ADAMTS-4 and -5, respectively) can be functionally dis-
tinguished from MMPs on the basis of different cleavage
sites in the G1-G2 interglobular domain of aggrecan. While
MMPs cleave at residues N341-F342, aggrecanases act at
NITEGE373-A374. The effects of TGF on MMP production
have been studied in detail11–13, but no information
exists on the effects of this growth factor on aggrecanase
expression by chondrocytes. Interestingly, a recent paper
by Yamanishi et al. showed that TGF stimulates expres-
sion of ADAMTS-4 by human synoviocytes24.
The aim of this study was to examine the effect of TGF
on aggrecanase production in human normal and osteo-
arthritic cartilage in vitro. To this end, cultures of isolated
chondrocytes were used to examine the expression at
mRNA level of ADAMTS-4 and -5 by RT-PCR. Tissue
explants were used to assay the release of proteo-
glycans and content of aggrecanase-generated NITEGE
neoepitope.
Materials and methods
REAGENTS
Dulbecco’s minimal essential medium/Ham’s F12
medium 50/50 mixture (DMEM/F12), fetal bovine serum
(FBS), Hanks’ balanced salt solution (HBSS), phosphate-
buffered saline (PBS) without Ca2+ and Mg2+, dispase and
100× concentrated stock solution of 104 IU/ml penicillin and
10 mg/ml streptomycin (PS), were from Invitrogen (Cergy-
Pontoise, France). Recombinant human TNF was from
R&D Systems, (Abingdon, U.K.). Recombinant human
TGF-1, recombinant murine IL-1, all-trans retinoic acid
(RA), bovine serum albumin (BSA), cetylpyridinium
chloride (CPC), dithiothreitol (DTT), ethylenediamino
tetraacetic acid (EDTA), guanidinium hydrochloride,
sodium dodecyl sulfate (SDS), Tween, chondroitinase
ABC, keratanase, papain and peroxidase-labeled anti
rabbit IgG were from Sigma (Saint Quentin Fallavier,
France). Collagenase type I was from Worthington
(Lakewood, NJ). Preimmune rabbit sera and antisera
against NITEGE were kindly provided by Pr. Michael T.
Bayliss and Dr J. Flannelly (Royal Veterinary College,
London, U.K.). The MMP inhibitor AG-3340 was synthe-
sized by the Division of Medicinal Chemistry at the Institut
de Recherches Servier (Suresnes, France). Working con-
centrations of IL-1, TNF and TGF were chosen on the
basis of already published reports10,12,24.
CARTILAGE SAMPLING
Cartilage samples were obtained from joints resected for
total hip or knee replacement because of osteosarcoma
(normal cartilage) or severe osteoarthritis. Full thickness
cartilage was taken from articular surfaces and used for
either chondrocyte isolation or tissue explant culture.
CHONDROCYTE CULTURE
Cartilage explants were finely minced, then digested for
5 h at 37°C in HBSS by a mixture of 3 mg/ml dispase and
2 mg/ml collagenase type I25. Isolated chondrocytes were
seeded in 6-well plates at the density of 3.5×105 cells/2 ml/
well or in 24-well plates at the density of 7×104 cells/0.5 ml/
well in DMEM/F12 medium supplemented with 10% FBS
and 1% PS. Medium was renewed 3 times/week, and after
12 days of culture, confluent cells were re-fed with DMEM/
F12 medium supplemented with 0.1% BSA and 1% PS.
After 24 h, medium was aspirated and cells were treated
with the same type of medium containing the treatment or
its vehicle.
RT-PCR STUDIES
For chondrocyte monolayers, total RNA was extracted
using Rneasy Mini Kit (Qiagen, Courtaboeuf, France)
according to the manufacturer’s specification. For explant
cultures, cartilage was reduced to small fragments of about
1 mm size, then transferred to 12-well plates at a ratio of
about 100 mg of tissue/2 ml of DMEM/F12 medium plus
0.1% BSA and 1% PS, containing the treatment or its
vehicle. At the end of treatment, tissue explants were
snap-frozen in liquid N2 and reduced to powder in a SPEX
Certiprep freezer mill (Metuchen, NJ). Total RNA was then
extracted as described by Reno et al.26. For samples of any
origin, 1 µg of total RNA was reverse transcribed (RT) for
1 h at 37°C, using oligo d(T)12-18 (Amersham Pharmacia,
Saclay, France) and Superscript II (Invitrogen), in a total
reaction volume of 20 µl. Two to 4 µl of the RT reaction was
used for each PCR reaction. Gene-specific oligonucleotide
primers were designed from the reported cDNA sequences
of human collagenase-1/MMP-127, stromelysin/MMP-328
and collagenase-3/MMP-1329 (Table I). Commercially
available primers were used for ADAMTS-4 and
ADAMTS-5 (sequences not disclosed) (R&D Systems,
Abingdon, U.K.), and for the house-keeping gene
2-microglobulin (2-M) (Table I) (Clontech, via Ozyme,
Saint Quentin Yvelines, France). For amplification of
ADAMTS-4 and ADAMTS-5, the protocol recommended by
the manufacturer was used. The amplicons produced had
the expected size of 501 bp for ADAMTS-4 and 524 bp
for ADAMTS-5. For amplification of MMPs and 2-
Microglobulin, the amplification profile involved 30–40
cycles of denaturation at 94°C for 30 s, annealing at 60°C
for 30 s and extension at 72°C for 1 min in a Gene Amp
PCR system 2400 (Perkin-Elmer, Courtaboeuf, France).
Vent-DNA polymerase from Biolabs (via Ozyme) was used
for MMPs and 2-Microglobulin. Hot start Taq polymerase
from Qiagen was used for ADAMTS-4 and ADAMTS-5. The
Table I
Primer sequences used for RT-PCR amplification of, MMP-1,
MMP-3, MMP-13 and 2-microglobulin (2-M)
Gene Primers (5′→3′) Size
(bp)
MMP-1 Forward: TGGGCTTGAAGCTGCTTACG 741
Reverse: AAGCTGCTCTCTGGGATCAACCG
MMP-3 Forward: TCACTCACTCACAGACCTGACTCG 467
Reverse: CCTTATCAGAAATGGCTGCATCG
MMP-13 Forward: GGAATTAAGGAGCATGGCGAC 512
Reverse: TATGCAGCATCAATACGGTTGG
2-M Forward: CTCGCGCTACTCTCTCTTTCTGG 335
Reverse: GCTTACATGTCTCGATCCCACTTAA
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PCR products were then separated by electrophoresis on a
1% agarose gel and photographed under UV light.
NITEGE DETECTION
Cartilage explants were reduced to small fragments of
about 1 mm size, then transferred to 6-well plates at a ratio
of about 40 mg of tissue/5 ml of DMEM/F12 medium plus
0.1% BSA and 1% PS, containing the treatment or its
vehicle. After 4 days of culture, the medium was discarded
and the tissue washed 3 times with 5 ml/well of PBS,
blotted dry, weighed and extracted in 40 volumes of 4 M
guanidinium chloride, 5 mM EDTA, 5 mM Na acetate,
pH 7.2 at 4°C for 3 days. The extract was exchanged
against 5 mM EDTA PBS, and concentrated using Ultrafree
and Centricon devices (Millipore, Saint Quentin Yvelines,
France) with a molecular weight cut-off of 10 kD. The
extracts were adjusted to the same volume/cartilage-mass
ratio of 4 µl/mg. The concentrates were deglycosylated by
0.1 U/ml of chondroitinase ABC and keratanase at 37°C for
18 h, reduced at 70°C for 10 min by NuPAGE reducing
agent (Invitrogen), and separated by sodium dodecylsul-
fate polyacrylamide gel electrophoresis30 on 4–12% gels
(Invitrogen) in parallel with Rainbow molecular weight
markers from BioRad (Ivry sur Seine, France) and
transferred onto Hybond ECL membranes (Amersham
Pharmacia), according to Tsang et al.31, using a Xcell
system from Invitrogen. Membranes were saturated with
1% BSA, 0.1% Tween PBS for 1 h, then probed with anti
NITEGE antisera (1/1000) in 1% BSA PBS for 1 h at
ambient temperature. After three washes, membranes
were probed with 1/2000 peroxidase-labeled anti rabbit IgG
in 1% BSA PBS for 1 h at ambient temperature. After four
washes, signals were visualized using an ECL detection kit
from Amersham Pharmacia. Blot images were captured by
an Agfa Arcus II scanner (Ista, Paris, France) controlled by
a Kodak 1D image-analysis software (Rochester, NY,
U.S.A).
CARTILAGE DEGRADATION
Cartilage explants were reduced to about 1 mm size,
then labeled with 100 µCi (3.7 MBq) of 35SO42− (Amersham
Pharmacia) in 25 ml of DMEM/F12 medium supplemented
with 10% FBS and 1% PS. The medium and the label were
renewed after 3 days of incubation. After three more days,
the unincorporated radioactivity was removed by six media
changes over 48 h using DMEM/F12 supplemented with
0.1% BSA and 1% PS. Each explant was then transferred
to 96-well plates into 0.25 ml of medium containing the
treatment or its vehicle. Each group was made of 8 to 12
fragments. After 2–3 days of incubation, conditioned media
were collected and the treatments renewed. After 3 more
days, the explants were collected and digested in 0.5 ml of
0.6 mg/ml papain, 1 mM EDTA, 0.25 mg/ml DTT 20 mM
sodium phosphate, pH 6.8 at 56°C for 16 h. Radioactivity in
the culture media and in the tissue digests was measured
by liquid scintillation using a -counter (Beckman, Gagny,
France). Proteoglycan degradation for each fragment was
expressed as the percentage of released radioactivity by
the formula: degradation=medium radioactivity/(medium
radioactivity+tissue radioactivity)×100.
PROTEOGLYCAN SYNTHESIS
Chondrocytes in 24-well plates were treated as
described above. After 24 h, cells were labeled with
1 µCi /well (37 KBq) of 35SO42− (Amersham Pharmacia) for
24 h. Medium was then collected and the cell layer washed
once with HBSS, then extracted with 0.25 ml/well of 4 M
guanidinium hydrochloride, 5 mM EDTA, 5 mM Na acetate,
pH 7.2 at 4°C for 2 days. Aliquots (50 µl) of medium and cell
extract from each well were then laid onto 4 cm squares of
Whatman 3MM filter paper and let dry. Absorbed proteogly-
cans were precipitated by immersion of the filters in 1%
CPC, 0.3 M NaCl. After two more washes in the same
solution, the filters were dried and the associated radio-
activity was measured by liquid scintillation counting. Total
CPC-precipitable radioactivity in the medium plus cell layer
was then calculated for each well.
STATISTICS
Control and treated groups were statistically com-
pared by analysis of variance followed by Dunnett’s test.
Significance was noted as follows: *** P<0.001; ** P<0.01;
* P<0.05. Shown data are averages±standard error of the
mean (SEM).
Results
EFFECTS OF TGF ON AGGRECANASE EXPRESSION IN
CHONDROCYTES FROM NORMAL CARTILAGE
The effects of TGF were first examined on the expres-
sion of ADAMTS-4 and -5 by cultured chondrocytes that
had been isolated from normal human cartilage (Fig. 1).
The effect of the growth factor was compared with that of
the inflammatory cytokines IL-1 and TNF. Analysis of
mRNA levels by RT-PCR showed that ADAMTS-4 was
weakly expressed in basal conditions, and strongly stimu-
lated by IL-1, TNF, and TGF. In contrast, ADAMTS-5
was expressed in a constitutive way, which was not appre-
ciably modified by any of the treatments. In this respect, it
was verified that PCR analysis of ADAMTS-5 was not
performed at a plateau level of message amplification.
Signals developed on gels were proportional to the number
Fig. 1. Effects of IL-1, TNF and TGF on mRNA expression
of ADAMTS-4, ADAMTS-5, MMP-1, MMP-3 and MMP-13, in
human chondrocytes from normal cartilage (female, 19 years-old).
Confluent chondrocytes were treated with 1 ng/ml IL-1, 10 ng/ml
TNF or 10 ng/ml TGF. After one day, mRNAs were extracted
and analysed by RT-PCR. House-keeping gene 2-microglobulin
was used as a control.
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of cycles, and no difference between treatments appeared
at 30, compared with 35 cycles (Fig. 2A). The strong stimu-
latory effect of TGF was specific to ADAMTS-4, since only
minor changes were caused by the growth factor on
expression of collagenases and stromelysin. In more detail,
TGF weakly stimulated MMP-13 expression, in agree-
ment with the report by Tardif et al.32, and also seemed to
cause a slight decrease in mRNA levels of MMP-3. Differ-
ently from the growth factor, IL-1 and TNF strongly
stimulated the expression of collagenases and stromelysin.
EFFECTS OF TGF ON AGGRECANASE EXPRESSION IN
CHONDROCYTES FROM DISEASED CARTILAGE
We then examined the effects of IL-1 and TGF on
aggrecanase expression in cultured chondrocytes that had
been isolated from the cartilage of joints at late stage OA.
Similarly to what observed in chondrocytes from normal
cartilage, the expression of ADAMTS-5 was constitutive
(Fig. 2B), while that of ADAMTS-4 was strongly stimulated
by TGF in two separate preparations of chondrocytes
from patients with OA (Fig. 3, A and B). Differently from
what observed in normal cartilage, 1 ng/ml IL-1 did not
stimulate ADAMTS-4 expression in these cultures, but
could still increase mRNA levels of MMP-1. However, in
chondrocytes from patients with OA, the response of
ADAMTS-4 to IL-1 was somewhat variable, since in a
different cell preparation the cytokine could still exert its
stimulatory action (Fig. 4). In the same experiment, TGF
stimulated ADAMTS-4 expression over a range of concen-
trations between 0.3 and 10 ng/ml, and had its maximum
effect around 1 ng/ml (Fig. 4). A time-course study showed
that maximal stimulation of ADAMTS-4 expression was
attained after one day, compared with 2 days of exposure
to TGF (Fig. 5). The experiments presented so far were all
realized using primary cultures of enzymatically isolated
chondrocytes. To verify that the stimulatory effect of TGF
on ADAMTS-4 expression was not an artifact due to
separation of chondrocytes from their natural environment,
freshly isolated explants of cartilage were treated by IL-1
or TGF for 1 day. PCR analysis of ADAMTS-4 message
showed that TGF increased, at least at 10 ng/ml, the
expression of ADAMTS-4 in explants isolated from two OA
patients (Fig. 6). Similarly to what observed in isolated
chondrocytes, the response to IL-1 was variable.
A: normal B:
TGFβ(ng/ml)   -     -     -     -    10          -     -    10
IL-1β (ng/ml)  -    1    10    -     -           -     1     -
TNFα (ng/ml)  -     -     -    10    -           -     -      -
35 cycles
30 cycles
Fig. 2. Analysis of ADAMTS-5 message following 30 or 35 PCR cycles. A: effects of IL-1 (1 and 10 ng/ml), TNF (10 ng/ml) and TGF
(10 ng/ml) on human chondrocytes from normal cartilage (female, 19 years-old). B: effects of IL-1 (1 ng/ml) and TGF (10 ng/ml) on
chondrocytes from OA cartilage (female, 76 years-old). Confluent chondrocytes were treated for one day, after which mRNAs were extracted
and analysed by RT-PCR.
Fig. 3. Effects of IL-1 and TGF on mRNA expression of ADAMTS-4, ADAMTS-5, and MMP-1 in human chondrocytes from two
osteoarthritic patients. A: female, 76 years-old. B: male, 68 years-old. Confluent chondrocytes were treated with 1 ng/ml IL-1 or 10 ng/ml
TGF. After one day, mRNAs were extracted and analysed by RT-PCR. House-keeping gene 2-microglobulin was used as a control.
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EFFECT OF TGF ON NITEGE LEVEL
If stimulated expression of ADAMTS-4 at mRNA level
translated into increased levels of the enzyme, the activity
of secreted ADAMTS-4 should result in accumulation of
specific aggrecan neoepitopes. Therefore, we examined
the effect of TGF on cartilage levels of NITEGE epitope.
Retinoic acid was used as a positive control of aggreca-
nase activation, according to Hughes et al.33. Four-day
incubation of explants of normal cartilage in the presence of
1 ng/ml TGF caused a marked increase of NITEGE signal
at 84 kD in western blots of tissue extracts (Fig. 7).
EFFECT OF TGF ON PROTEOGLYCAN DEGRADATION
It was finally examined if TGF could stimulate proteogly-
can degradation in cartilage explants from patients with
OA. For this, forming aggrecan was labelled by 35SO4 for 6
days, then the explants were repeatedly washed over 2
days, in order to eliminate the unincorporated label and
loosely bound proteoglycans. The explants were then
treated by either TGF, IL-1 or TNF and the release of
radiolabeled material in the media was measured after 3
and 6 days. This protocol allows the measurement of
proteoglycan release due to degradation, differently from
colorimetric assays, which do not discriminate between
degraded and newly synthesized material. TGF at 0.5, 5
and 50 ng/ml dose-dependently stimulated proteoglycan
degradation, its effect being stronger during the second half
of the treatment, in which, significant increases were seen
at all concentrations tested (Fig. 8, A and B). In this assay,
neither the effects of IL-1 (1 ng/ml) nor those of TNF
(10 ng/ml) reached statistical significance (Fig. 8, A and B).
Higher (10×) concentrations did not further increase the
effects of the two cytokines (data not shown). It was then
examined if TGF-induced release of radiolabeled material
could be blocked by a proteinase inhibitor and therefore
considered to be due to proteoglycan degradation. We
used for this AG-3340 (prinomastat), a large-spectrum
inhibitor of the enzymatic activity of mature MMPs, with Ki
values between 3×10−11 and 3×10−10 M for MMP-2, -3, -9,
-13 and -1434. This compound also inhibits aggrecanase
activity, but less effectively, since a concentration around
1 µM is needed for a 50% reduction in activity of this
enzyme35. It was found that AG-3340 significantly inhibited
TGF-induced proteoglycan degradation, starting at 10−6
M, both in cartilage from patients with OA (Fig. 9, A and B)
and in normal tissue (Fig. 10, A and B). The inhibitor had no
effect at a lower concentration (0.1 µM), in agreement with
the hypothesis that aggrecanases but not MMPs are
involved in proteoglycan loss caused by TGF. Neverthe-
less, the inhibitor was unable to completely block the effect
of TGF on proteoglycan release (Figs. 9 and 10), even
though it was effective at preventing the increase of
aggrecanase-generated NITEGE (Fig. 11). This suggests
that aggrecanases partly mediate proteoglycan loss
induced by TGF, the balance being due to enzymes
other than metalloproteinases. It was also examined if
TGF, in parallel with ADAMTS-4 induction and stimu-
lation of proteoglycan degradation, still exerted its anabolic
action on chondrocyte cultures, through stimulation of
Fig. 4. Dose response of TGF on mRNA expression of ADAMTS-4 and ADAMTS-5 in human chondrocytes from osteoarthritic (female, 69
years-old) cartilage. Confluent chondrocytes were treated with TGF at concentrations between 0.3 and 10 ng/ml. After 1 day, mRNAs were
extracted and analysed by RT-PCR. House-keeping gene 2-microglobulin was used as a control.
Fig. 5. Time course of TGF effect on mRNA expression of ADAMTS-4 in human chondrocytes from osteoarthritic (female, 79 years-old)
cartilage. Confluent chondrocytes were treated with TGF (0.1 to 10 ng/ml). After 1 and 2 days, mRNAs were extracted and analysed by
RT-PCR. House-keeping gene 2-microglobulin was used as a control.
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proteoglycan synthesis. Data in Table II show that
the growth factor significantly increased proteoglycan
synthesis, at 1 and 10 ng/ml.
Discussion
In this study, TGF stimulated ADAMTS-4 expression at
mRNA level in human articular chondrocytes. This effect
was first observed in cells from normal cartilage of a young
individual, and confirmed in chondrocytes from a number of
elder patients at late-stage OA. It was not possible to
extend our study to chondrocytes from normal cartilage of
individuals in the same age range as the OA patients. Other
agents already known to activate ADAMTS-4 expression
are TNF and IL-1. We confirm that these two cytokines
upregulate ADAMTS-4 expression in chondrocytes from
normal cartilage. In addition, as expected, they strongly
stimulated the expression of MMP-1, -3 and -13. The fact
that TGF strongly stimulates ADAMTS-4, while having
little if any effect on these MMPs, suggests that TGF
action is not mediated via the induction of TNF or IL-1,
and that the growth factor and the two cytokines act
through different pathways. ADAMTS-5 appeared to be
regulated differently than ADAMTS-4, since its expression
Il-1β (ng/ml) -        1
 TGFβ (ng/ml)      -         -       1      10
β2-M
ADAMTS-4
A
ADAMTS-4
β2-M
Il-1β (ng/ml) -        1
 TGFβ (ng/ml)      -         -       1      10
B
Fig. 6. Effect of TGF and IL-1 on ADAMTS-4 expression in cartilage explants from 2 osteoarthritic patient (A: male, 67 years-old; B: female,
53 years old). Tissue explants were treated with 1 and 10 ng/ml TGF or 1 ng/ml IL-1. After 1 (A) and 2 days (B), mRNAs were extracted
and analysed by RT-PCR. House-keeping gene 2-microglobulin was used as a control.
MW (kDa)
134 →
82 →
41 →
RA (µM)         -       1        -
TGFβ (ng/ml)     -        -       1
Fig. 7. Effect of TGF and retinoic acid (RA) on tissue levels of
aggrecanase-generated NITEGE neoepitope in normal cartilage
(female, 52 years-old). Cartilage explants were treated with 1 µM
RA or 1 ng/ml TGF. After 4 days, tissue extracts were assayed for
NITEGE content by western blot. MW: molecular weight markers.
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was not increased neither by TGF, similarly to what shown
by Yamanishi et al. in synoviocytes24, nor by the inflamma-
tory cytokines IL-1 and TNF. However, while our PCR
data describe expression changes, they do not quantify the
relative levels of mRNA for ADAMTS-4 and ADAMTS-5 in
chondrocytes. Therefore they do not allow any prediction
on the proportions in which the two enzymes are produced,
and the measure in which the observed changes of
ADAMTS-4 expression affect the total aggrecanase pool.
An initial report of ADAMTS-1 displaying aggrecanase
activity36 was not confirmed by Malfait et al.37. For this
reason, ADAMTS-1 was not included in this study.
For these expression studies, chondrocytes were enzy-
matically isolated, then grown in monolayers. This pro-
cedure implies some degree of proliferation before
confluence is attained and also forces chondrocytes into a
continuous bidimensional layer. This condition is opposite
to that existing in vivo, where little or no proliferation takes
place, and chondrocytes are dispersed in a tridimensional
matrix without any direct cell to cell contact. It leads as a
consequence to chondrocyte dedifferentiation, and pro-
gressive slowdown of matrix synthesis as passaging pro-
ceeds38. In order to minimize this drift, we limited cell
proliferation by using primary cultures seeded at the
highest density allowed by the number of collected
cells. Immunohistochemistry showed aggrecan deposition
throughout the monolayers as well as more discrete stain-
ing for collagen II (not shown). We believe, therefore, that
the employed culture conditions allowed acceptable pres-
ervation of the chondrocytic phenotype. More importantly,
stimulation of ADAMTS-4 expression by TGF was verified
in tissue explants and therefore confirmed to be a pertinent
response of chondrocytes to this growth factor. Expression
of MMPs and aggrecanases was analysed by RT-PCR.
This method does not allow precise quantification of the
mRNA level of a given gene. However, the effect of TGF
on ADAMTS-4 expression was very marked and could be
confirmed in all the experiments performed, also using
different primer pairs (not shown). That the method gives
reliable information is also suggested by the fact that IL-1
stimulated aggrecanase expression, in agreement with the
results of Curtis et al.39, although this effect was not
observed in all chondrocyte preparations. The lack of
response of ADAMTS-4 to IL-1 in some cultures from
osteoarthritic cartilage could be due, among other reasons,
to decreased receptor sensitivity, because of previous long
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Fig. 8. Effect of TGF, IL-1 and TNF on proteoglycan degra-
dation in explants of human osteoarthritic cartilage (female, 75
years-old). 35SO4-labeled cartilage explants were treated with 0.5,
5 and 50 ng/ml TGF, 1 ng/ml IL-1 or 10 ng/ml TNF. Treatments
were renewed after 3 days and culture was ended at day 6.
Proteoglycan degradation was measured as percentage of
released radioactive material for the time periods day 0 to day 3
(panel A), and day 3 to day 6 (panel B). Asterisks indicate a
significant difference between treated and control. *P<0.05;
**P<0.01; ***P<0.001. Data are averages±SEM; N=8/group.
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Fig. 9. Effect of AG3340 on TGF-induced proteoglycan degra-
dation in explants of human osteoarthritic cartilage (female, 59
years old). 35SO4-labeled cartilage explants were treated with
1 ng/ml TGF in the absence or presence of AG-3340 between
10−7 and 10−4 M. Treatment was renewed after 2 days and culture
was ended at day 5. Proteoglycan degradation between days 0
and 2 (panel A) and between days 2 and 5 (panel B),
was calculated as percentage of released radioactive material.
Significant difference between control and TGF alone is indicated
by the symbols ##(P<0.01) and ###(P<0.001). Significant differ-
ence between TGF alone, and TGF plus AG-3340 is indicated
by the symbols *(P<0.05) and **(P<0.05). Data are averages±SEM;
N=12/group.
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term exposure to the cytokine in joints at a late stage of
disease1,4–6.
The stimulatory effect of TGF on ADAMTS-4 expression
in isolated chondrocytes and cartilage explants was
associated to increased levels of aggrecanase-generated
NITEGE neoepitope in cartilage explants, which could be
blocked by the MMP and aggrecanase inhibitor AG-3340.
This higher aggrecanase activity might be due to increased
production of ADAMTS-4 following upregulated expression
at mRNA level. However, our data cannot prove a precise
link between mRNA expression, protein production and
enzyme activation, and it would be also possible that
TGF-induced aggrecan degradation be partly or totally
due to increased enzymatic activity of basally produced
ADAMTS-4 and ADAMTS-5. In this respect, it was recently
shown by Gao et al.40 that C-terminal cleavage of
ADAMTS-4 progressively increased aggrecanase activity
as the size of the enyme decreased from 75 to 60 and
50 kD.
In our experiments on cartilage fragments, TGF also
stimulated proteoglycan degradation, which could be partly,
but not totally blocked by the MMP and aggrecanase
inhibitor AG-3340. The need of high inhibitor concentration
for significant decrease of proteoglycan degradation was in
agreement with the involvement of aggrecanases, but not
MMPs, in TGF-induced matrix loss. Residual degradation
in the presence of AG-3340 could be due to proteases
other than metalloproteinases, possibly of the cathepsin
family41. The stimulatory effect of TGF on ADAMTS-4
production and aggrecanase-mediated cartilage degra-
dation is somewhat surprising in the light of the largely
accepted view of this growth factor essentially being an
anabolic and anti-catabolic agent. In this respect, we veri-
fied that the culture conditions we used still allowed TGF
to stimulate proteoglycan synthesis in chondrocyte mono-
layers. It would seem therefore that TGF activates the
turn-over of aggrecan, through a combined stimulation of
its synthesis and aggrecanase-mediated degradation. In
addition, the results we obtained on cartilage are in very
good agreement with the recent article by Yamanishi
et al.24, in which TGF was reported to stimulate
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Fig. 10. Effect of AG3340 on TGF-induced proteoglycan degra-
dation in explants of human normal cartilage (male, 18 years old).
35SO4-labeled cartilage explants were treated with 1 ng/ml TGF
in the absence or presence of AG-3340 between 10−7 and 10−5 M.
Treatment was renewed after 3 days and culture was ended at day
6. Proteoglycan degradation between days 0 and 3 (panel A) and
between days 3 and 6 (panel B), was calculated as percentage of
released radioactive material. Significant difference between con-
trol and TGF alone is indicated by the symbol ##(P<0.01).
Significant difference between TGF alone, and TGF plus
AG-3340 is indicated by the symbol *(P<0.05). Data are
averages±SEM; N=12/group.
AG-3340 (10-5 M)     -       -       +
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Fig. 11. Effect of AG3340 on TGF-induction of aggrecanase-
generated NITEGE neoepitopes in explants of human normal
cartilage (same as in Fig. 10). Cartilage explants were treated with
1 ng/ml TGF in the absence or presence of 10−5 M AG-3340. After
5 days of treatment (media renewed on day 2), tissue extracts
were assayed for NITEGE content by western blot. MW: molecular
weight markers.
Table II
Effect of TGF on proteoglycan synthesis by chondrocytes from
OA cartilage. Confluent primary chondrocytes were incubated in
the absence or presence of TGF at 0.1, 1 and 10 ng/ml. After one
day, cultures were labeled with 35SO4. After one extra day, radio-
activity incorporated in CPC-precipitable material was measured.
Asterisks indicate a significant difference between TGF and
control
Proteoglycan synthesis (dpm/well)
Control 6870±338
TGF 0.1 ng/ml 7075±160
TGF 1 ng/ml 10930±391***
TGF 10 ng/ml 10508±199***
***P<0.001.Data are averages±SEM; N=4.
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ADAMTS-4 expression in human synoviocytes, and have
no effect on ADAMTS-5, which was produced in a consti-
tutive way. Our data are also in agreement with the recent
report by Mi et al.19, showing that overexpression of TGF
in knees of normal or arthritic rabbits, resulted in increased
proteoglycan degradation. This sustains the observation by
Elford et al.17 of a loss of cartilage proteoglycans after
multiple TGF intra-articular injections in rabbits. Interest-
ingly, this treatment did not have any effect on collagen
content, suggesting that it selectively stimulated
proteoglycan-degrading enzymes such as aggrecanases.
Sparing of collagen seems to exclude a role of MMPs,
which collectively degrade all matrix components4, and
makes as a consequence less probable the hypothesis,
suggested by van Beuningen, that the in vivo degradative
effect of TGF are due to cytokine production secondary to
synovial hyperplasia and monocytic infiltration16,18. In fact,
as we confirm in this paper, inflammatory cytokines strongly
stimulate MMP production, which should result in both
proteoglycan and collagen loss. Stimulation of aggre-
canase expression and proteoglycan degradation in vitro
suggests that TGF role in osteoarthritis could go beyond
early stimulation of chondrocyte synthetic activity and
osteophyte formation. The results by Mi et al.19 confirm
indeed that the net effect of TGF overexpression in joints
would be more toward loss than preservation or repair of
cartilage as previously thought. As a result, administration
of this growth factor as therapy of OA would become
questionable. Active TGF was shown to be present in the
synovial fluid of osteoarthritic patients at an average con-
centration of 4 ng/ml, which is compatible with marked
biological effects42. In this situation, TGF could cause an
increase of aggrecan turnover, through stimulation of both
its synthesis and degradation. Proteoglycan fragments
produced by TGF-stimulated aggrecanase could repre-
sent the inflammatory signal that triggers cytokine produc-
tion by synoviocytes and chondrocytes6, and leads to
progression of the disease to the destructive phase,
characterized by MMP production, massive collagen and
aggrecan degradation, superficial fibrillation, and tissue
erosion.
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